These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

910 related items for PubMed ID: 29587666

  • 1. Cost effectiveness analysis of afatinib versus pemetrexed-cisplatin for first-line treatment of locally advanced or metastatic EGFR mutation positive non-small-cell lung cancer from the Singapore healthcare payer's perspective.
    Tan PT, Aziz MIA, Pearce F, Lim WT, Wu DB, Ng K.
    BMC Cancer; 2018 Mar 27; 18(1):352. PubMed ID: 29587666
    [Abstract] [Full Text] [Related]

  • 2. Cost-Effectiveness and Value of Information of Erlotinib, Afatinib, and Cisplatin-Pemetrexed for First-Line Treatment of Advanced EGFR Mutation-Positive Non-Small-Cell Lung Cancer in the United States.
    Ting J, Tien Ho P, Xiang P, Sugay A, Abdel-Sattar M, Wilson L.
    Value Health; 2015 Sep 27; 18(6):774-82. PubMed ID: 26409604
    [Abstract] [Full Text] [Related]

  • 3. Cost-effectiveness analysis of osimertinib for first-line treatment of locally advanced or metastatic EGFR mutation positive non-small cell lung cancer in Singapore.
    Aziz MIA, Foo WYX, Toh CK, Lim WT, Ng K.
    J Med Econ; 2020 Nov 27; 23(11):1330-1339. PubMed ID: 32886557
    [Abstract] [Full Text] [Related]

  • 4. EGFR mutation-guided use of afatinib, erlotinib and gefitinib for advanced non-small-cell lung cancer in Hong Kong - A cost-effectiveness analysis.
    You JHS, Cho WCS, Ming WK, Li YC, Kwan CK, Au KH, Au JS.
    PLoS One; 2021 Nov 27; 16(3):e0247860. PubMed ID: 33647045
    [Abstract] [Full Text] [Related]

  • 5. Cost-effectiveness of afatinib, gefitinib, erlotinib and pemetrexed-based chemotherapy as first-line treatments for advanced non-small cell lung cancer in China.
    Gu X, Zhang Q, Chu YB, Zhao YY, Zhang YJ, Kuo D, Su B, Wu B.
    Lung Cancer; 2019 Jan 27; 127():84-89. PubMed ID: 30642557
    [Abstract] [Full Text] [Related]

  • 6. Afatinib versus cisplatin plus gemcitabine for first-line treatment of Asian patients with advanced non-small-cell lung cancer harbouring EGFR mutations (LUX-Lung 6): an open-label, randomised phase 3 trial.
    Wu YL, Zhou C, Hu CP, Feng J, Lu S, Huang Y, Li W, Hou M, Shi JH, Lee KY, Xu CR, Massey D, Kim M, Shi Y, Geater SL.
    Lancet Oncol; 2014 Feb 27; 15(2):213-22. PubMed ID: 24439929
    [Abstract] [Full Text] [Related]

  • 7. Cost-effectiveness of Osimertinib in the First-Line Treatment of Patients With EGFR-Mutated Advanced Non-Small Cell Lung Cancer.
    Aguiar PN, Haaland B, Park W, San Tan P, Del Giglio A, de Lima Lopes G.
    JAMA Oncol; 2018 Aug 01; 4(8):1080-1084. PubMed ID: 29852038
    [Abstract] [Full Text] [Related]

  • 8. Budget Impact Analysis of Afatinib for First-Line Treatment of Patients with Metastatic Non-Small Cell Lung Cancer with Epidermal Growth Factor Receptor Exon 19 Deletions or Exon 21 Substitution Mutations in a U.S. Health Plan.
    Graham J, Earnshaw S, Burslem K, Lim J.
    J Manag Care Spec Pharm; 2018 Jun 01; 24(6):544-553. PubMed ID: 29799327
    [Abstract] [Full Text] [Related]

  • 9. Cost-Effectiveness Analysis of Afatinib versus Gefitinib for First-Line Treatment of Advanced EGFR-Mutated Advanced Non-Small Cell Lung Cancers.
    Chouaid C, Luciani L, LeLay K, Do P, Bennouna J, Perol M, Moro-Sibilot D, Vergnenègre A, de Pouvourville G.
    J Thorac Oncol; 2017 Oct 01; 12(10):1496-1502. PubMed ID: 28751244
    [Abstract] [Full Text] [Related]

  • 10. Cost-effectiveness of gefitinib, icotinib, and pemetrexed-based chemotherapy as first-line treatments for advanced non-small cell lung cancer in China.
    Lu S, Ye M, Ding L, Tan F, Fu J, Wu B.
    Oncotarget; 2017 Feb 07; 8(6):9996-10006. PubMed ID: 28036283
    [Abstract] [Full Text] [Related]

  • 11. Cost-effectiveness of continuation maintenance pemetrexed after cisplatin and pemetrexed chemotherapy for advanced nonsquamous non-small-cell lung cancer: estimates from the perspective of the Chinese health care system.
    Zeng X, Peng L, Li J, Chen G, Tan C, Wang S, Wan X, Ouyang L, Zhao Z.
    Clin Ther; 2013 Jan 07; 35(1):54-65. PubMed ID: 23328269
    [Abstract] [Full Text] [Related]

  • 12. Cost-utility of afatinib and gefitinib as first-line treatment for EGFR-mutated advanced non-small-cell lung cancer.
    Wang H, Zeng C, Li X, Wang Y, Li X, Ge W.
    Future Oncol; 2019 Jan 07; 15(2):181-191. PubMed ID: 30320506
    [Abstract] [Full Text] [Related]

  • 13. The cost-effectiveness of dacomitinib in first-line treatment of advanced/metastatic epidermal growth factor receptor mutation-positive non-small-cell lung cancer (EGFRm NSCLC) in Sweden.
    Nilsson FOL, Gal P, Houisse I, Ivanova JI, Asanin ST.
    J Med Econ; 2021 Jan 07; 24(1):447-457. PubMed ID: 33754924
    [Abstract] [Full Text] [Related]

  • 14. [Efficacy of first-line afatinib versus chemotherapy in EGFR mutation positive pulmonary adenocarcinoma].
    Sárosi V, Balikó Z.
    Magy Onkol; 2014 Dec 07; 58(4):325-9. PubMed ID: 25517450
    [Abstract] [Full Text] [Related]

  • 15. Afatinib versus cisplatin plus pemetrexed in Japanese patients with advanced non-small cell lung cancer harboring activating EGFR mutations: Subgroup analysis of LUX-Lung 3.
    Kato T, Yoshioka H, Okamoto I, Yokoyama A, Hida T, Seto T, Kiura K, Massey D, Seki Y, Yamamoto N.
    Cancer Sci; 2015 Sep 07; 106(9):1202-11. PubMed ID: 26094656
    [Abstract] [Full Text] [Related]

  • 16. Carboplatin plus pemetrexed offers superior cost-effectiveness compared to pemetrexed in patients with advanced non-small cell lung cancer and performance status 2.
    Schluckebier L, Garay OU, Zukin M, Ferreira CG.
    Lung Cancer; 2015 Sep 07; 89(3):274-9. PubMed ID: 26143106
    [Abstract] [Full Text] [Related]

  • 17. Clinical effectiveness and cost-effectiveness of first-line chemotherapy for adult patients with locally advanced or metastatic non-small cell lung cancer: a systematic review and economic evaluation.
    Brown T, Pilkington G, Bagust A, Boland A, Oyee J, Tudur-Smith C, Blundell M, Lai M, Martin Saborido C, Greenhalgh J, Dundar Y, Dickson R.
    Health Technol Assess; 2013 Jul 07; 17(31):1-278. PubMed ID: 23886301
    [Abstract] [Full Text] [Related]

  • 18. Symptom control and quality of life in LUX-Lung 3: a phase III study of afatinib or cisplatin/pemetrexed in patients with advanced lung adenocarcinoma with EGFR mutations.
    Yang JC, Hirsh V, Schuler M, Yamamoto N, O'Byrne KJ, Mok TS, Zazulina V, Shahidi M, Lungershausen J, Massey D, Palmer M, Sequist LV.
    J Clin Oncol; 2013 Sep 20; 31(27):3342-50. PubMed ID: 23816967
    [Abstract] [Full Text] [Related]

  • 19. First-Line Afatinib versus Chemotherapy in Patients with Non-Small Cell Lung Cancer and Common Epidermal Growth Factor Receptor Gene Mutations and Brain Metastases.
    Schuler M, Wu YL, Hirsh V, O'Byrne K, Yamamoto N, Mok T, Popat S, Sequist LV, Massey D, Zazulina V, Yang JC.
    J Thorac Oncol; 2016 Mar 20; 11(3):380-90. PubMed ID: 26823294
    [Abstract] [Full Text] [Related]

  • 20. Cost-Effectiveness Analysis of Sunitinib versus Interferon-Alfa for First-Line Treatment of Advanced and/or Metastatic Renal Cell Carcinoma in Singapore.
    Pruis SL, Aziz MIA, Pearce F, Tan MH, Wu DB, Ng K.
    Int J Technol Assess Health Care; 2019 Jan 20; 35(2):126-133. PubMed ID: 30854989
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 46.